Luteolin Cognition Randomized Trial: What the Evidence Says

Quick Answer

Luteolin Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• These compounds are widely present in plants and are included in the human and animal diet, being found mainly in the vacuoles of plant cells in the form of C-glycosides or O-glycosides, acting as attractants to pollinators and symbionts [e.g., sunscreens against ultraviolet (UV) radiation, allelochemicals, and antimicrobial and antiherbivore factors]. [Piva Maiara (2026); evidence level 3]
• Among the classes, isoflavones (present in soybean), flavonols (present in teas, onions, red wine, olive oil, among others), and flavones (present in fruit skins, buckwheat, red pepper, among others) are the flavonoids found in the greatest quantity in foods consumed by humans. [Piva Maiara (2026); evidence level 3]
• Figure 1 Thus, in the present review we aimed to summarize the preclinical and clinical evidence of selected nutraceuticals, focusing on biotin, flavonoids especially luteolin, folic acid, Huperzine A, Lion's mane, olive oil polyphenols (oleuropein and hydroxytyrosol [HT]), and palmitoylethanolamide (PEA). [Venetsanaki Vasiliki (2026); evidence level 3]
• The present narrative review highlights current mechanistic insights, as well as evidence from experimental and clinical studies regarding their potential roles in supporting cognitive function, modulating neuroinflammation, and mitigating neurodegenerative processes. [Venetsanaki Vasiliki (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For luteolin cognition randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Piva Maiara (2026). Flavonoids as Nutraceuticals to Treat Inflammatory Diseases: Focusing on Quercetin, Kaempferol, Luteolin, Apigenin, Epicatechin and Their Effects on Hepatic, Nervous, and Pulmonary Systems. DOI: 10.3390/foods15122159. PMCID: PMC13298688. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13298688/
• Venetsanaki Vasiliki (2026). Natural Molecules for Brain Health and Resilience. DOI: 10.3390/ijms27104343. PMCID: PMC13207114. PMID: 42196321. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13207114/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.